Patient case highlights secondary tumor after CAR-T treatment for myeloma
A case study of a 63-year-old male with early relapse of multiple myeloma (MM) indicated that treatment with a chimeric antigen receptor (CAR)
Cellular Therapy
Multiple Myeloma
Leukemia
Lymphoma
Long-term use of TNF inhibitors for psoriasis, RA may increase risk for leukemia, lymphoma but not other cancers
A study assessed the risk of cancer in patients receiving long-term treatment with tumor necrosis factor (TNF)-alpha inhibitors and found that cumulative use
Multiple Myeloma
Combination monoclonal antibody treatment induces responses but also infections in MM
In a phase 1b/2 study, researchers assessed the feasibility of combining talquetamab and teclistamab for the treatment of relapsed or refractory multiple myeloma
Multiple Myeloma
A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients
The combination of isatuximab, bortezomib, and lenalidomide with limited dexamethasone is a feasible treatment option for transplant-ineligible older patients with multiple myeloma (MM),
Lymphoma
News
Interim PET scan after 4 treatment cycles predicts outcomes in primary mediastinal B-cell lymphoma patients
An interim positron emission tomography (PET) scan after four treatment cycles emerged as the strongest predictor of outcomes for primary mediastinal B-cell lymphoma
Lymphoma
FDA clears Ventana hematopathology test for diagnosing BCL
The US Food and Drug Administration (FDA) has granted clearance to the Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail, an in-situ
Myeloproliferative Neoplasms
Addition of ropeginterferon alfa-2b to standard PV care is cost effective
The addition of ropeginterferon alfa-2b (ropegIFNα) to phlebotomy for the treatment of polycythemia vera (PV) was “cost effective,” according to an Austrian study
Multiple Myeloma
FDA grants Orphan Drug Designation for small-molecule MM therapy
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for OPN-6602, an oral small-molecule EP300/CBP inhibitor, for patients with multiple
Lymphoma
FDA clears IND for novel relapsed or refractory NHL therapy
The US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for LTZ-301, a first-in-class bispecific myeloid engager immunotherapy,
Multiple Myeloma
Real-world study observes ‘superior’ outcomes with cilta-cel versus ide-cel for myeloma
A real-world study compared the two chimeric antigen receptor (CAR) T-cell therapies idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for the treatment of
